Literature DB >> 31611362

Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations.

Francesco Saladini1, Alessia Giannini2, Adele Boccuto2, Filippo Dragoni2, Alice Appendino2, Edoardo Albanesi2, Ilaria Vicenti2, Maurizio Zazzi2.   

Abstract

Second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) dolutegravir (DTG), bictegravir (BIC), and cabotegravir (CAB) showed a high genetic barrier to resistance and limited cross-resistance with first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG). In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q148H/K/R plus one to two additional INSTI mutations.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  HIV-1 resistance; bictegravir; cabotegravir; dolutegravir; integrase inhibitors; phenotypic assay

Mesh：

Substances：

Year:  2019        PMID： 31611362      PMCID： PMC7187585          DOI： 10.1128/AAC.01717-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes.

Authors:  Kristel Van Laethem; Yoeri Schrooten; Kris Covens; Nathalie Dekeersmaeker; Paul De Munter; Eric Van Wijngaerden; Marc Van Ranst; Anne-Mieke Vandamme
Journal:  J Virol Methods       Date:  2008-09-02       Impact factor: 2.014

2.  Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors.

Authors:  Francesco Saladini; Alessia Giannini; Adele Boccuto; Ilaria Vicenti; Maurizio Zazzi
Journal:  J Clin Lab Anal       Date:  2017-03-17       Impact factor: 2.352

3.  Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.

Authors:  Said A Hassounah; Ahmad Alikhani; Maureen Oliveira; Simrat Bharaj; Ruxandra-Ilinca Ibanescu; Nathan Osman; Hong-Tao Xu; Bluma G Brenner; Thibault Mesplède; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

4.  Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors.

Authors:  Wendy W Zhang; Peter K Cheung; Natalia Oliveira; Marjorie A Robbins; P Richard Harrigan; Aniqa Shahid
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

5.  COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification.

Authors:  Daniel Struck; Glenn Lawyer; Anne-Marie Ternes; Jean-Claude Schmit; Danielle Perez Bercoff
Journal:  Nucleic Acids Res       Date:  2014-08-12       Impact factor: 16.971

6.  Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.

Authors:  Manuel Tsiang; Gregg S Jones; Joshua Goldsmith; Andrew Mulato; Derek Hansen; Elaine Kan; Luong Tsai; Rujuta A Bam; George Stepan; Kirsten M Stray; Anita Niedziela-Majka; Stephen R Yant; Helen Yu; George Kukolj; Tomas Cihlar; Scott E Lazerwith; Kirsten L White; Haolun Jin
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

7.  Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.

Authors:  Steven J Smith; Xue Zhi Zhao; Terrence R Burke; Stephen H Hughes
Journal:  Retrovirology       Date:  2018-05-16       Impact factor: 4.602
  7 in total
  3 in total

1.  High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.

Authors:  Emmanuel Ndashimye; Yue Li; Paul S Reyes; Mariano Avino; Abayomi S Olabode; Cissy M Kityo; Fred Kyeyune; Immaculate Nankya; Miguel E Quiñones-Mateu; Stephen D Barr; Eric J Arts
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.758

Review 2.  A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.

Authors:  Alexa Vyain Zhao; Rustin D Crutchley; Rakesh Chowdary Guduru; Kathy Ton; Tammie Lam; Amy Cheng Min
Journal:  Retrovirology       Date:  2022-10-22       Impact factor: 3.768

3.  Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

Authors:  Michelle L D'Antoni; Kristen Andreatta; Rima Acosta; Hal Martin; Silvia Chang; Ross Martin; Kirsten L White
Journal:  J Acquir Immune Defic Syndr       Date:  2022-04-01       Impact factor: 3.771
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.